Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M R Stockler

Showing results (31-40 of 49) with videos related to

Pageof 5
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 30, 2005
Patients' preferences for adjuvant chemotherapy in early breast cancer: what makes AC and CMF worthwhile now?V M Duric, M R Stockler, S Heritier, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 28, 2017
Patients' preferences for adjuvant sorafenib after resection of renal cell carcinoma in the SORCE trial: what makes it worthwhile?P L Blinman, I D Davis, A Martin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 9, 2017
Quality of life predicts overall survival in women with platinum-resistant ovarian cancer: an AURELIA substudyF T Roncolato, E Gibbs, C K Lee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 1996
Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end pointsI F Tannock, D Osoba, M R Stockler, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|January 1, 2013
Results of a 7-day aprepitant schedule for the prevention of nausea and vomiting in 5-day cisplatin-based germ cell tumor chemotherapyI N Olver, P Grimison, M Chatfield, et al.
Lancet (London, England)|March 20, 2001
Comparison of two standard chemotherapy regimens for good-prognosis germ-cell tumours: a randomised trial. Australian and New Zealand Germ Cell Trial GroupG C Toner, M R Stockler, M J Boyer, et al.
European Journal of Cancer Care|May 26, 2017
e-TC: Development and pilot testing of a web-based intervention to reduce anxiety and depression in survivors of testicular cancerL E Heiniger, A B Smith, I Olver, et al.
Internal Medicine Journal|August 2, 2014
Testosterone deficiency and quality of life in Australasian testicular cancer survivors: a prospective cohort studyB O'Carrigan, M Fournier, I N Olver, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|June 22, 2015
Hope, optimism and survival in a randomised trial of chemotherapy for metastatic colorectal cancerPenelope E Schofield, M R Stockler, D Zannino, et al.
British Journal of Cancer|August 22, 2014
Methylated Glutathione S-transferase 1 (mGSTP1) is a potential plasma free DNA epigenetic marker of prognosis and response to chemotherapy in castrate-resistant prostate cancerK L Mahon, W Qu, J Devaney, et al.
Pageof 5

Showing results (31-40 of 49) with videos related to

Sort By:
Pageof 5
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 30, 2005
Patients' preferences for adjuvant chemotherapy in early breast cancer: what makes AC and CMF worthwhile now?V M Duric, M R Stockler, S Heritier, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 28, 2017
Patients' preferences for adjuvant sorafenib after resection of renal cell carcinoma in the SORCE trial: what makes it worthwhile?P L Blinman, I D Davis, A Martin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 9, 2017
Quality of life predicts overall survival in women with platinum-resistant ovarian cancer: an AURELIA substudyF T Roncolato, E Gibbs, C K Lee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 1996
Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end pointsI F Tannock, D Osoba, M R Stockler, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|January 1, 2013
Results of a 7-day aprepitant schedule for the prevention of nausea and vomiting in 5-day cisplatin-based germ cell tumor chemotherapyI N Olver, P Grimison, M Chatfield, et al.
Lancet (London, England)|March 20, 2001
Comparison of two standard chemotherapy regimens for good-prognosis germ-cell tumours: a randomised trial. Australian and New Zealand Germ Cell Trial GroupG C Toner, M R Stockler, M J Boyer, et al.
European Journal of Cancer Care|May 26, 2017
e-TC: Development and pilot testing of a web-based intervention to reduce anxiety and depression in survivors of testicular cancerL E Heiniger, A B Smith, I Olver, et al.
Internal Medicine Journal|August 2, 2014
Testosterone deficiency and quality of life in Australasian testicular cancer survivors: a prospective cohort studyB O'Carrigan, M Fournier, I N Olver, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|June 22, 2015
Hope, optimism and survival in a randomised trial of chemotherapy for metastatic colorectal cancerPenelope E Schofield, M R Stockler, D Zannino, et al.
British Journal of Cancer|August 22, 2014
Methylated Glutathione S-transferase 1 (mGSTP1) is a potential plasma free DNA epigenetic marker of prognosis and response to chemotherapy in castrate-resistant prostate cancerK L Mahon, W Qu, J Devaney, et al.
Pageof 5